Search filters

List of works by Brian Schwartz

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

scientific article published on 3 October 2017

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

scientific article published on 3 January 2013

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors

scientific article

A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors

scientific article

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada [...]

scientific article

A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy

scientific article published on 17 February 2016

ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease

scientific article published on 06 October 2016

An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin.

scientific article

Brief Report: Tivantinib in Combination with Erlotinib Versus Erlotinib Alone for EGFR Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study.

scientific article published on 27 December 2017

Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092)

scientific article published on 03 February 2020

Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma.

scientific article published on 23 January 2018

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

scientific article published on October 2006

Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor

scientific article

Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors.

scientific article published on 30 April 2009

Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

scientific article published on 31 May 2011

In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).

scientific article published on 16 March 2018

In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy

scientific article

In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor

scientific article

Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania

scientific article published in PLoS ONE

Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis

scientific article published on 15 October 2018

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

scientific article

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

scientific article published on 07 March 2011

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

scientific article published on 8 July 2005

Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer.

scientific article published in June 2007

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

scientific article

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

scientific article published on March 2007

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

scientific article published on 24 April 2006

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

scientific article published on 13 July 2015

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation

scientific article

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma

scientific article published on 22 January 2017

Quantifying survival in patients with Proteus syndrome.

scientific article

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

scientific article published on 3 February 2018

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

scientific article published on 18 July 2011

Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.

scientific article published in November 2004

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

scientific article published on 23 August 2018

Sorafenib in advanced clear-cell renal-cell carcinoma

scientific article

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

scientific article published on August 2006

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

scientific article

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

scientific article published on 09 August 2018

The burden of illness associated with renal cell carcinoma in the United States.

scientific article published in September 2007

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial

scientific article

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

article

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

scientific article

To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound

scientific article published on 11 September 2006

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

scientific article published on 25 August 2016

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.

scientific article published on April 2017

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma

scientific article published on 28 September 2012

Paulina is supported by:

About Paulina

Help